[HTML][HTML] Bioactive lipid lysophosphatidic acid species are associated with disease progression in idiopathic pulmonary fibrosis

M Neighbors, Q Li, SJ Zhu, J Liu, WR Wong, G Jia… - Journal of Lipid …, 2023 - ASBMB
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with significant mortality.
Prognostic biomarkers to identify rapid progressors are urgently needed to improve patient …

[HTML][HTML] Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis

SB Montesi, SK Mathai, LN Brenner… - BMC Pulmonary …, 2014 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with no
effective medical therapies. Recent research has focused on identifying the biological …

[HTML][HTML] Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis–a potential biomarker role for LysoPC

B Rindlisbacher, C Schmid, T Geiser, C Bovet… - Respiratory …, 2018 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease of unknown etiology.
Patients present loss of lung function, dyspnea and dry cough. Diagnosis requires …

[HTML][HTML] Cellular and molecular control of lipid metabolism in idiopathic pulmonary fibrosis: clinical application of the lysophosphatidic acid pathway

Y Nakamura, Y Shimizu - Cells, 2023 - mdpi.com
Idiopathic pulmonary fibrosis (IPF) is a representative disease that causes fibrosis of the
lungs. Its pathogenesis is thought to be characterized by sustained injury to alveolar …

[HTML][HTML] Lysophosphatidic acid species are associated with exacerbation in chronic obstructive pulmonary disease

Q Li, W Wong, A Birnberg, A Chakrabarti, X Yang… - BMC Pulmonary …, 2021 - Springer
Background Chronic obstructive pulmonary disease (COPD) exacerbations are
heterogenous and profoundly impact the disease trajectory. Bioactive lipid lysophosphatidic …

[HTML][HTML] Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by Lipidomics

F Yan, Z Wen, R Wang, W Luo, Y Du, W Wang… - BMC Pulmonary …, 2017 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is an irreversible interstitial pulmonary
disease featured by high mortality, chronic and progressive course, and poor prognosis with …

[HTML][HTML] Challenges in accurate quantitation of lysophosphatidic acids in human biofluids

JM Onorato, P Shipkova, A Minnich, AF Aubry… - Journal of lipid …, 2014 - ASBMB
Lysophosphatidic acids (LPAs) are biologically active signaling molecules involved in the
regulation of many cellular processes and have been implicated as potential mediators of …

Lysophosphatidic acid, ceramide 1-phosphate and sphingosine 1-phosphate in peripheral blood of patients with idiopathic pulmonary fibrosis

T Tanaka, K Koyama, N Takahashi, K Morito… - The Journal of Medical …, 2022 - jstage.jst.go.jp
Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonias.
Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) are signaling lipids that …

Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy

R Chen, J Dai - Journal of Molecular Medicine, 2023 - Springer
Idiopathic pulmonary fibrosis (IPF) is a chronic irreversible interstitial lung disease
characterized by a progressive decline in lung function. The etiology of IPF is unknown …

Lysophosphatidic acid is an important mediator of fibroblast recruitment in IPF

I Scott - Thorax, 2008 - thorax.bmj.com
Lysophosphatidic acid (LPA) and its G protein-coupled receptor (LPA1) play key pathogenic
roles in idiopathic pulmonary fibrosis (IPF). Previous research has highlighted the …